

PCT

Print Out (Original in Electronic Form)

VIII-2-1	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application ASTRAZENECA AB and CANCER RESEARCH TECHNOLOGY LIMITED is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-1(i v)		an assignment from FINLAY, Maurice Raymond Verschoyle to AstraZeneca UK Limited, dated 19 June 2018 (19.06.2018)

PCT

Print Out (Original in Electronic Form)

VIII-2-2	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application ASTRAZENECA AB and CANCER RESEARCH TECHNOLOGY LIMITED is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-2(i v)		an assignment from HOWARD, Martin Richard to AstraZeneca UK Limited, dated 18 June 2018 (18.06.2018)

PCT

Print Out (Original in Electronic Form)

VIII-2-3	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application ASTRAZENECA AB and CANCER RESEARCH TECHNOLOGY LIMITED is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-3(i v)		an assignment from GOLDBERG, Frederick Woolf to AstraZeneca UK Limited, dated 18 June 2018 (18.06.2018)

PCT

Print Out (Original in Electronic Form)

VIII-2-4	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application ASTRAZENECA AB and CANCER RESEARCH TECHNOLOGY LIMITED is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-4(i v)		an assignment from TING, Atilla Kuan Tsuei to AstraZeneca UK Limited, dated 18 June 2018 (18.06.2018)

PCT

Print Out (Original in Electronic Form)

VIII-2-5	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application ASTRAZENECA AB and CANCER RESEARCH TECHNOLOGY LIMITED is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-5(i v)		an assignment from AstraZeneca UK Limited to ASTRAZENECA AB, dated 04 July 2018 (04.07.2018)

PCT

Print Out (Original in Electronic Form)

VIII-2-6	Declaration: Entitlement to apply for and be granted a patent Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate: Name (LAST, First)	In relation to this international application ASTRAZENECA AB and CANCER RESEARCH TECHNOLOGY LIMITED is entitled to apply for and be granted a patent by virtue of the following:
VIII-2-6(i v)		an assignment from ASTRAZENECA AB to ASTRAZENECA AB and CANCER RESEARCH TECHNOLOGY LIMITED, dated 04 July 2018 (04.07.2018)